Trials / Completed
CompletedNCT01221259
A Randomized, Double-blind, Placebo-controlled, Sequential Ascending, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2212 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study is designed as a single ascending dose study in healthy subjects to evaluate safety, tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) in plasma and Cerebrospinal (CSF) following single oral doses of E2212.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E2212 | single ascending doses ranging from 10mg to 250mg |
| DRUG | placebo | a single dose of matching placebo |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2011-10-01
- Completion
- 2012-11-01
- First posted
- 2010-10-14
- Last updated
- 2013-05-22
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01221259. Inclusion in this directory is not an endorsement.